Advertisement

Biotechnology and Bioprocess Engineering

, Volume 17, Issue 2, pp 413–419 | Cite as

Interfering transbody-mediated Her2 gene silencing induces apoptosis by G0/G1 cell cycle arrest in Her2-overexpressing SK-BR-3 breast cancer cells

  • Aeyung Kim
  • Dong-Ki Choi
  • Eun-Sil Sung
  • Jee Sun Yun
  • Myung-Hee Kwon
  • Yong-Sung KimEmail author
Research Paper

Abstract

We previously isolated an interfering transbody, 4MH2, which penetrated the cytosol of living cells and preferentially hydrolyzed the target Her2 (ErbB2) mRNA, resulting in Her2 gene silencing followed by apoptotic cell death in Her2-overexpressing breast cancer cells. Here, we report the apoptotic cell death mechanism mediated by 4MH2-induced Her2 gene silencing in Her2-overexpressing SK-BR-3 breast cancer cells, in comparison with a small interfering RNA (siRNA) targeting Her2 mRNA (Her218-siRNA). 4MH2 induced G0/G1 cell cycle arrest to cause apoptotic cell death in SK-BR-3 cells by triggering specific signaling pathways associated with Her2 knockdown, including upregulation of G0/G1 cell cycle arrest-associated p21Cip1 and p27Kip1, downregulation of cyclin D1, inhibition of Akt phosphorylation, and downregulation of antiapoptotic Bcl-xL, which are comparable to those mediated by Her218-siRNA. Our results suggest that 4MH2-mediated Her2 gene silencing can trigger the downstream signaling pathways caused by Her2 downregulation, comparable to those mediated by the corresponding siRNA.

Keywords

antibody engineering gene silencing cell penetration cell cycle arrest apoptosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moasser, M. M. (2007) The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 26: 6469–6487.CrossRefGoogle Scholar
  2. 2.
    Tai, W., R. Mahato, and K. Cheng (2010) The role of HER2 in cancer therapy and targeted drug delivery. J. Control Release. 146: 264–275.CrossRefGoogle Scholar
  3. 3.
    Yoon, S., Y. S. Kim, H. Shim, and J. Chung (2010) Current perspectives on therapeutic antibodies. Biotechnol. Bioproc. Eng. 15: 709–715.CrossRefGoogle Scholar
  4. 4.
    Choudhury, A., J. Charo, S. K. Parapuram, R. C. Hunt, D. M. Hunt, B. Seliger, and R. Kiessling (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int. J. Cancer 108: 71–77.CrossRefGoogle Scholar
  5. 5.
    Faltus, T., J. Yuan, B. Zimmer, A. Kramer, S. Loibl, M. Kaufmann, and K. Strebhardt (2004) Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/ neu-overexpressing breast cancer cells. Neoplasia. 6: 786–795.CrossRefGoogle Scholar
  6. 6.
    Yang, G., K. Q. Cai, J. A. Thompson-Lanza, R. C. Bast, and J. Liu (2004) Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J. Biol. Chem. 279: 4339–4345.CrossRefGoogle Scholar
  7. 7.
    Jackson, A. L. and P. S. Linsley (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9: 57–67.CrossRefGoogle Scholar
  8. 8.
    Persengiev, S. P., X. Zhu, and M. R. Green (2004) Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA. 10: 12–18.CrossRefGoogle Scholar
  9. 9.
    Lee, W. R., J. Y. Jang, J. S. Kim, M. H. Kwon, and Y. S. Kim (2010) Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies. Nucleic Acids Res. 38: 1596–1609.CrossRefGoogle Scholar
  10. 10.
    Kim, D. S., S. H. Lee, J. S. Kim, S. C. Lee, M. H. Kwon, and Y. S. Kim (2009) Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting. Biochem. Biophys. Res. Commun. 379: 314–318.CrossRefGoogle Scholar
  11. 11.
    Kim, Y. R., J. S. Kim, S. H. Lee, W. R. Lee, J. N. Sohn, Y. C. Chung, H. K. Shim, S. C. Lee, M. H. Kwon, and Y. S. Kim (2006) Heavy and light chain variable single domains of an anti- DNA binding antibody hydrolyze both double- and singlestranded DNAs without sequence specificity. J. Biol. Chem. 281: 15287–15295.CrossRefGoogle Scholar
  12. 12.
    Jang, J. Y., J. G. Jeong, H. R. Jun, S. C. Lee, J. S. Kim, Y. S. Kim, and M. H. Kwon (2009) A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity. Cell Mol. Life Sci. 66: 1985–1997.CrossRefGoogle Scholar
  13. 13.
    Lee, C. H., K. J. Park, E. S. Sung, A. Kim, J. D. Choi, J. S. Kim, S. H. Kim, M. H. Kwon, and Y. S. Kim (2010) Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 107: 9567–9571.CrossRefGoogle Scholar
  14. 14.
    Sung, E. S., A. Kim, J. S. Park, J. Chung, M. H. Kwon, and Y. S. Kim (2010) Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human Tcell acute lymphoblastic leukemia cells. Apoptosis. 15: 1256–1269.CrossRefGoogle Scholar
  15. 15.
    Sung, E. S., K. J. Park, S. H. Lee, Y. S. Jang, S. K. Park, Y. H. Park, W. J. Kwag, M. H. Kwon, and Y. S. Kim (2009) A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Mol. Cancer Ther. 8: 2276–2285.CrossRefGoogle Scholar
  16. 16.
    Avrameas, A., L. Gasmi, and G. Buttin (2001) DNA and heparin alter the internalization process of anti-DNA monoclonal antibodies according to patterns typical of both the charged molecule and the antibody. J. Autoimmun. 16: 383–391.CrossRefGoogle Scholar
  17. 17.
    Fonseca, S. B., M. P. Pereira, and S. O. Kelley (2009) Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 61: 953–964.CrossRefGoogle Scholar
  18. 18.
    Wang, T., J. Zhao, J. L. Ren, L. Zhang, W. H. Wen, R. Zhang, W. W. Qin, L. T. Jia, L. B. Yao, Y. Q. Zhang, S. Y. Chen, and A. G. Yang (2007) Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res. 67: 11830–11839.CrossRefGoogle Scholar
  19. 19.
    Le, X. F., F. X. Claret, A. Lammayot, L. Tian, D. Deshpande, R. LaPushin, A. M. Tari, and R. C. Bast (2003) The role of cyclindependent kinase inhibitor p27Kip1 in anti-HER2 antibodyinduced G1 cell cycle arrest and tumor growth inhibition. J. Biol. Chem. 278: 23441–23450.CrossRefGoogle Scholar

Copyright information

© The Korean Society for Biotechnology and Bioengineering and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Aeyung Kim
    • 1
  • Dong-Ki Choi
    • 1
  • Eun-Sil Sung
    • 1
  • Jee Sun Yun
    • 1
  • Myung-Hee Kwon
    • 2
  • Yong-Sung Kim
    • 1
    Email author
  1. 1.Department of Molecular Science and TechnologyAjou UniversitySuwonKorea
  2. 2.Department of MicrobiologyAjou University School of MedicineSuwonKorea

Personalised recommendations